chi fda report-embargoed

7/31/2019 CHI FDA Report-Embargoed

1/12

MANAGING PRIORITIES:THERAPEUTIC AREA VARIATION IN

FDA DRUG REGULATION

MAY 2012

Bkgd: FDA Dg Rg Pm ....................................................

Tp A V ......................................................................................

T Imp Rb D ..............................................................................

Appdx .................................................................................................................

1

2

8

10


2/12

chi-caliornia healthcare institute 1

may 2012

p w bjv. T

pvd pd pm

U.S. Fd d Dg Adm

(FDA) w p ppv

dg d bg. T bd dy, Competitiveness and Regulation: Te FDA and

the Future o Americas Biomedical Industry (2011),

dd w B Cg Gp

(BCG). O d bjv p w

d mp d FDA

pm m p .

Ogy, , g py d

Agy d v pd

ppv dg. Idd, FDAd v ggd ppv

gy pd vd mmm

bmd v. B

w d bd by d db

gd xmp w gy dd

m d Agy pm

ggd. A Cg z Pp

Dg U F A (PDUFA), w gg

dp mg p my,

, p ppy FDA: my,

p pp d p g-pmg g Agy.

BACKGROUND: FDA DRUG

REGULATION PERFORMANCE

O ky dg pbd

Competitiveness and Regulation w mkd

m ppv dg, bgg

FY 2007 d g y p PDUFA IV y, w d FY 2008. F

xmp, Fg 1 w dg bmd

FDA 2008, d PDUFA IV, xpd

vg ppv m 18.9 m, 28

p v vg PDUFA III m

14.7 m.

T

FIGURE 1.


3/12

2 chi-caliornia healthcare institute

may 2012

m mp g pd

ppv pp v b py

vw, w d 45 p dg

ppvd Am, b j 5 p

d by Ep Md Agy

(EMA). T FDA ppvd py vw dg

vg 186 dy, w dd vw

m dg m pd vgd 424 dy.1

THERAPE UTIC AREA VARIATIONS

I 2011, vd FDA bg

y mpvg dg ppv

m. I Ob, Agy pbdFY 2011 Innovative Drug Approvals, w

dmd 35 vv dg d

FY2011, dg dv g p C,

1 Wg d N MA, Nw Dg

Appv ICH C: 2002-2011, C

Iv Rgy S (Ap 2012), pp. 1, 6.

I 2009, vg dg ppv m mgy

mpvd m PDUFA III pd (by 1.3

p) 14.5 m. A m m, g,

FDA d m PDUFA qm

mm gy d w x

m py pp d 10 m

dd pp. Lkg w dg

bmd Agy 2008, Fg 2 w

ppv m gg g; 45 p

bm md p m

y b Agy k gy .

Hwv, y bd vw w

dg bm g FY 2011 gg

mpvm ppv m (Fg 3).

R d pbd by C Iv

Rgy S Ud Kgdm

wd md ppv m dg

ppvd U.S. w

Ep d Jp. I pd 2002-2011,

FIGURE 2.


4/12


may 2012

FIGURE 3.

p, pm, d v d d

p d. Adg p, b

dg w ppvd b g d PDUFA, d mjy

vw y. T Agy mpd

by g xpdd ppv pwy

, my , md ,

wg m, w d. I

m v, y, Fd C

R pbd d g g Agy

pm gy dg, g m

v gy pd v b ppvd

U.S. d Ep.2

2 U.S. Fd d Dg Adm, FY 2011

Innovative Drug Approvals, Nvmb, 2011, pp. 4-8;

Sm A. Rb, J D. A, E V. Sg, Dp

Cm FDA Rvw P, Nw C Dg

R P S Ud S, Health Afairs,

J 2011.

T mp dg. Ad mg

p , gy, d

d p d bg p. B y FDA d gg m d

p. T FDA m;

g dv vw m, dpdg

pd p . A d Fg

4, bw 2000 d 2011, gy d -

v dg, xmp, xpd

vw, d 10-15 m. F

g dv, v ym,

g-, py, . vg vw

m d m 20 30 m.

N g xp d

pm mg p . Sm d

my b y m mpd, w w

bmk w py dd mm

v dg. Dg gg dd


5/12


may 2012

FIGURE 4.

v ym (CNS), xmp,v d py g ppv m. W

dd k Azm, Pk d

mp mp wdpd g,

mpx bgy md m y

v g dg dvpm. T

gy p m m mpxy.

Dg 15-y pd pg 1996 2010,

vg C Sdy

Dg Dvpm d m

p p ppv m CNS dg w 32m g dg. F CNS

dg mp p k

102.2 m, b 40 p g -

CNS dg. Mw, ppv m CNS

dg vgd 20.3 m, 13 p g

-CNS p. Cmmg

d, pp vg Jp A.DM d, Ag I xpd CNS dg

dvpm d ppv m w g

vg, I w mw pd x

w y w g, ddg, I d

pg -CNS dg w w-d-

m m ky v py vw

g m FDA w CNS dg.3

Idy, gzg FDA m

p d dd p q, wd p b gm

bw g d pb . Y,

m dg, g v g b.

3 C Sdy Dg Dvpm,

Dg CNS D k 35% Lg Dvp

O Dg, M 6, 2012.


6/12


may 2012

Byd CNS dd, db, by, d

dv d x m, d gwg,

dmg . Rgy pwy

, wv, g w y.

Ad w g pmm dvpg pd

d, w v dg p

b dppd.4

W dy d v mmy

k, mm wdm Agy

, , gd b-k

dd, dmdg m d v g

pd. A S CEO d m m

Pm R d M

Am (PRMA) Cp Vb

xpd, Y g pmy

d bmg mw gd v

pzd dg, w p d

FDA ppd p d-

xg py -vg m.

mk w gg m d

pmy , w d m y d

k-b pdby w w v pd.5

Ay dg bm

dg. O d, w

Fg 5, gy bm v d

gy 2000, py d, p,

xp m f d pdb

4 N V Cp A, V Sg:

T C Ivm U.S. Bmd Iv d Impv F.D.A. Rm, Ob 2011. T vy

dd m g d v mmy:

pdby FDA g dg

vm y-g mp.

5 Ry MBd, S CEO Cg FDA

C Up Rgy Pwy Nw Md, Reuters,

Jy 20, 2012.

vw p. O d, g

vw m d p d

pdb, bm g- d

dv pd dppd dby

v m m pd.

W FDA mgy gd p

gy dg, Agy gv dvp

db d by dg, xmp,

mxd g. U y, dv

m d w md m xvy

dv dg dvpm. Evg

k -dv p w

q g p p d

p g p. Lkg

mp FDA 2008 gd ddg

dv k dg yp 2 db:

Rvw m dbd -mdg

dg.

T m vdgp d

J 2008, 30 m NDA w

d, dd p bm m

FDA qm. (T dg w ppvd EU 2007.)

T mb dmzd p d

p-y NDA d m

2.5 d 4 d, pvy, gd

w pbd.

Oby U.S. d pdm

pp, w b -d d

d b. Id kg p

dg dvpm, wv, Agy

Edg d Mb Dg Advy

Cmm y vd q dv

k m by dg dd

m w p d

dd vd k. T p w d


7/12


may 2012

qm wd dd y ppv

p d p dd $100

m.6

F my dg, p d FDA

v b wg p d

d mpvy w p py

b gd v m

d b p v g b.

Mw, v p 15 y y by

6 C. Vk, P. Bd, A Ay Imp

FDA Gd Addg Cdv Rk

Dg yp 2 Db C Dvpm,

Contemporary Clinical rials, My 2011, pp. 324-32; Hd

Ldd, H Sd Ndd Oby Dg, FDA

Adv Sy,Nature News Blog, M 30, 2012.

dg md U.S. mk;

w wdw wg p-ppv

dv v. T d Agy

d dd . I 2007,

d d gd by dg, g

-y w mmm 4,500 p:

3,000 dmzd m m, 1,500

pb. A pp, g, dp

by m 30 p 50 p,

vy g m d d w

g g p pw vd dy.

Tkg b k, Sjy K, dg

dvy p, mmd, W

wg d dg k

dpdg b. I y v dg w

5 p wg v w 10 p

FIGURE 5.


8/12


may 2012

15 p, w mg p m k. S,

b-k m by d db

pd g bd gy, w

FDA pd g-m d (

w dmzd gp) d gdp.7

Byd md, d v d

p dm. Ad p

v bd m dd , gg

p gp, md p d d

f, v mp ppvg

w dg. T m gy

1970 d 1980 w, w d

w AIDS, d-d gz d

w FDA: by gg

d xp; by g

p w md p; d

by ppg dy Cg, w vg

d ppp qd Agy

.

Ogzd dvy b p d

d FDA dj p. T Agyd dd m , d d

p w gzd d

dv w, bm , d

pp. T d d p

pw gzg v

p d p d Agy

dvp ggg m. Umy,

d wy, d AIDS dmy

dmd pw p p,

py pg FDA dp xby dd y d fy by kg

7 Rb Dw, Sy I d Rg Dv

Ev C Dvpm P, Spmb

29, 2011, p://mmy.ppd.m//-p/

y--d-g-dv-v--

dvpm-p

vwp p d

d. I q m,

pd Agy d wd b

v k m p .8

A dp PDUFA 1992, FDA

dd d ppv p. T

py gd dg pp -

g d kd v p.

Lgy p AIDS pdm,

Agy wd p bm d

g dp, d vd

b p. F AIDS dg,

m g dp w by

wd pp HIV v d

p. Ad ppv w d:

p w qd d p-mkg

d vd dg

b. B b v AIDS d

dd. S pgm bg, 81

pd ppvd d d ppv, 32

v gd AIDS, 29 , d 20

dd.9

W ddb FDA wd

mpz dd w w-gzd, v

, b w pp

my mp pb k

g dvy. V, , m

m v dg wd. B

pp w b m m v, m

z v , y pd

by d-d mm. Ty y

8 D Cp, Reputation and Power:

Organizational Image and Pharmaceutical Regulation at the

FDA(2010), pp. 391-402.

9 J Wdk, FDA U F 2012: Hw

Iv Hp P d Jb, Sm b

Cmm Egy d Cmm Sbmm

H, U.S. H Rpv, Ap 18, 2012, p. 7.


9/12


may 2012

gz v ppv

FDA. Idd, xp pv

AIDS V Advy C

(AVAC). Fdd 1995 d ppd by

dg pb gz, dg$14 m m B d Md G

Fd, AVAC bb FDA m

dvpm pwy AIDS v.10

THE IM PORTANCE OF RE LIABLE DATA

W Cg vy dg PDUFA V

d dd g mpv Agy

pm m,

dy FDA y y.

B, Hvd D Cp p

dy FDA dg g,

pw vy p y d

gv Agy. Owg d

Cg d v dd,

dmv Agy b dwd w

by p, , d v

pp w pdd w py

md md d gd d p d d

py g wd.11

W my b d

g j w m FDA pm

mgm. Hy w ,

b, dg gg d w g

p pb md d ggv p

dvy gp b m m py vw

d d ppv. Exp w

d AIDS gg g d m

10 AIDS V Advy C Rv $14

m m G Fd,Medical News, Ag 21,

2007.

11 Cp, Reputation and Power, p. 750.

dmv dd d, b wd,

mg p xby dpd

x p d dvpg . PDUFA

V pvd Agy

d g dg. B bggdg ppv b gm w pb

d w q mpvm

mgm, d w d mm

. F , p g d

Agy Ob 2011 pp, Driving

Biomedical Innovation gg.12 T m

w wk p, w FDA d

dy vg wk g

dvpm p.

S, m-d pp mgm

w g md g d. W v

d g d wkg v p

w y w BCG d FDA, mg

Agy d d g b

ddg w p, d w

pm m v gd v m. S

w bv g v () gy

gg d yzg b pb d;(b) pdg pm m dg

x PDUFA y d k pm

y d gdy; d () g

gm mg FDA, dy,

d Cg d d w y

pd m pb m

Agy pm. I m

Agy g m 20 p

Am pd, d dpd gy

dy , b

wy d b kg mm

d y.

12 U.S. Fd d Dg Adm, Driving

Biomedical Innovation: Initiatives to Improve Products or

Patients, Ob, 2011.


10/12


may 2012

W p g dg d

bg, FDA , bm, d mgm

gz. T Agy q dy

p bm d m v

d, d yz ddw dg dd d v.

Ag wy, FDA g d

b w pm. W bv b

d ky b mpvd d mkg

w dg vw p d d

fy Agy.

B dyg b d d

d. I m wy, pbm md

M Lw bk,Moneyball: Te Art o

Winning an Unair Game(2003). I y

Okd A bb m, d

g mg By B, w, w m

m bdg m mp,

dvpd y, vd bd pp

mbg wg m. B

g w vd wdm bb

p py, , mg,

d w b w m pmw dpy wd. F y, bb d

k gd k bg vg,

d vg d bd w

mp m ggg py. Bd

v y pp, B wd g

k -b pg d ggg pg

w m gy d w

d m.

I k Uvy C

S F, J Wdk, d

FDA C Dg Ev d R,

mkd Agy w pb

kg 55,000 pm m; my,

ggd, y dd vw m

pmy wk ppvg w md.

Cy, y w mpd

FDA pm mm ,

FDA-RACK, xpd dqy

my dvd p mm

w w Agy pm d . Pp, , w dd

d d wdm

d mp FDA d (d my

dy pp, w). dy w v

pdd y d

mg g d. W dd

FDA d dy b dvp

vv pp d y

pm.

PDUFA V p x p ,

gg pp bw FDA d

dy. I mp g

m gy d: pp Agy

pm bmd v;

g dd fy;

b mpv p pb y

w mp g b pv-

vm w dg d bg d dv pb . I g

vw, pb d m d

mpv bmd dy

w d m . W mm

vm, x g bkg

g d w v

mz. N w jb pd m.

Cmm Hmbg d FDA

Am Iv Agy, w mg b

dd m p

.13 B p w , d bv

PDUFA V w b mp p

mpg .

13 Mg Hmbg, Am Iv Agy:

T FDA,Wall Street Journal, Ag 1, 2011.


11/12


may 2012

APPENDIX

Cdg w PDUFA V, Cg

dg dd gv pp

pdg dg ppv.

eFasterAccesstoSpecializedTreatments

(FAST)Act. Idd by Rp. S (R-

FL) d w (D-NY), FAS p w

d ppv pwy dg

w FDA gg

d -g d k

m. Amg g, b wd

b dg p q -k

dg by FDA. I wd

g xby dgg

vvg dd. P FAS

A dd H d v

PDUFA V.

eTransformingtheRegulatory

EnvironmenttoAccelerateAccessto

Treatments(TREAT)Act. Idd

S by S. Ky Hg (D-NC). Sm

FAS, b gy v d ppv d

-k p pd dvpm

p p w -

REPORT AUTHORS

g d. I m

md d, gy dvg

dd , d gd p

-g d.

eAdvancingBreakthrougherapiesforPatientsAct. C-pd by S.

M B (D-CO), O H

(R-U), d Rd B (R-NC),

b wd xb pwy

FDA v pd

g d d

w pmy vd d

dg my dm b

mpvm v xg p

m y g dp.

I dd, g g

FDA dg

f pb. I dd

d d gd p w

k bkg, d ppv,

d/ k dg. Ad

qm Sy HHS

mm dpd y, w

y, v qy, fy, dpdby FDA mp w

g.

PROJECT TEAM

Sm Gd

Partner and Managing Director

T B Cg Gp

Dvd L. G, P.D.

President and CEO

CHI-C H I

dd Gw, CHI

N Bkd, CHI

H Cmb, CHI


12/12


may 2012

T California Healthcare Institute (CHI), dd 1993,

dpd p gz dvd g

d dvg py wd C

bmd mmy. CHI b mmbp

m 275 dg bmd mp, dm d

d mp vvd ppg

bmd mmy. T m CH I , dvp, d dv

p d pm bmd ,

bgy, pm d md dv v

C. CHI wb www..g. Fw w

@, Fbk, LkdI d Yb.

T Boston Consulting Group (BCG) gb mgm

g m d wd dg dv b

gy. W p w m pv, pb, d

--p g dy g-

v pp, dd m g, dm p. O mzd pp mb

dp g dym mp d mk

w b v gz.

T v b mpv

dvg, bd m pb gz, d g

. Fdd 1963, BCG pv mpy w 75

f 42 .

HEADQUARTERS888 Prospect Street, Suite 220

La Jolla, California 92037

Tel: 858-551-6677 | Fax: 858-551-6688

[email protected]

SACRAMENTO1201 K Street, Suite 1840

Sacramento, California 95814

Tel: 916-233-3497 | Fax: 916-233-3498

WASHINGTON, D .C.1608 Rhode Island Ave., N.W., Room 238

Washington, D.C. 20036

Tel: 202-974-6313 | Fax: 202-974-6330

2012 California Healthcare Institute. All rights reserved.

chi fda report-embargoed

Documents